This company listing is no longer active
Amryt Pharma Management
Management criteria checks 2/4
Key information
Joe Wiley
Chief executive officer
US$1.7m
Total compensation
| CEO salary percentage | 43.4% |
| CEO tenure | 8.3yrs |
| CEO ownership | 1.1% |
| Management average tenure | 3.3yrs |
| Board average tenure | 3.6yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2022 | n/a | n/a | -US$790k |
| Jun 30 2022 | n/a | n/a | US$3m |
| Mar 31 2022 | n/a | n/a | US$3m |
| Dec 31 2021 | US$2m | US$747k | US$1m |
| Sep 30 2021 | n/a | n/a | -US$88m |
| Jun 30 2021 | n/a | n/a | -US$81m |
| Mar 31 2021 | n/a | n/a | -US$92m |
| Dec 31 2020 | US$2m | US$727k | -US$105m |
| Sep 30 2020 | n/a | n/a | -US$87m |
| Jun 30 2020 | n/a | n/a | -US$92m |
| Mar 31 2020 | n/a | n/a | -US$87m |
| Dec 31 2019 | US$1m | US$588k | -US$63m |
Compensation vs Market: Joe's total compensation ($USD1.72M) is above average for companies of similar size in the German market ($USD1.29M).
Compensation vs Earnings: Joe's compensation has increased whilst the company is unprofitable.
CEO
Joe Wiley (51 yo)
8.3yrs
Tenure
US$1,720,000
Compensation
Dr. Joseph A. Wiley, also known as Joe, M.D. was the Founder of Amryt Pharma plc and serves as its Chief Executive Officer since 2015. He has been a Director at Amryt Pharma plc since April 19, 2016. Dr. W...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 8.3yrs | US$1.72m | 1.1% € 9.4m | |
| CFO, COO & Company Secretary | 8.3yrs | US$939.00k | 0.51% € 4.4m | |
| Chief Compliance Officer | 2.3yrs | no data | no data | |
| General Counsel | 5.6yrs | no data | no data | |
| Head of Marketing & Head of APAC | 4.3yrs | no data | no data | |
| Head of Human Resources | no data | no data | no data | |
| Head of Medical Affairs | no data | no data | no data | |
| President of Americas | 2yrs | no data | no data | |
| Chief Medical Officer | less than a year | no data | no data | |
| President of EMEA Region | less than a year | no data | no data |
3.3yrs
Average Tenure
54.5yo
Average Age
Experienced Management: 3N9A's management team is considered experienced (3.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 7yrs | US$1.72m | 1.1% € 9.4m | |
| Independent Non-Executive Director | 3.6yrs | US$88.00k | 0.023% € 199.6k | |
| Independent Non-Executive Director | 3.6yrs | US$58.00k | 0.0070% € 59.9k | |
| Independent Non-Executive Director | 3.6yrs | US$60.00k | 0.0078% € 66.5k | |
| Independent Non-Executive Director | 3.6yrs | US$80.00k | 0% € 0 | |
| Independent Non-Executive Chairman of the Board | 7yrs | US$88.00k | 0.61% € 5.2m | |
| Independent Non-Executive Director | 1.7yrs | US$20.00k | 0% € 0 | |
| Independent Non-Executive Director | 3.6yrs | US$65.00k | 0.031% € 266.1k | |
| Independent Non-Executive Director | 1.7yrs | US$20.00k | 0% € 0 |
3.6yrs
Average Tenure
59yo
Average Age
Experienced Board: 3N9A's board of directors are considered experienced (3.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/04/14 17:10 |
| End of Day Share Price | 2023/04/11 00:00 |
| Earnings | 2022/09/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Amryt Pharma plc is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michelle Gilson | Canaccord Genuity |
| Brandon Folkes | Cantor Fitzgerald & Co. |
| Andrew Young | Davy |